Psychoses like schizophrenia cost billions of dollars annually and derail the lives of people struggling with the disease.
Biogen to acquire Reata Pharmaceuticals in $7 billion deal
Biogen on Friday said it would acquire Reata Pharmaceuticals, the maker of an approved therapy for a rare neurological condition, in a deal worth $7.3
July 28, 2023